

**AMENDMENTS TO THE CLAIMS**

1-14. (canceled)

15. (previously presented) A method of preparing a crystal of ACE protein comprising the steps of :

(a) culturing host cells comprising an underglycosylated ACE protein;

(b) purifying the underglycosylated ACE protein; and

(c) crystallising the underglycosylated ACE protein.

16. (previously presented) A method according to claim 15 wherein the ACE protein is underglycosylated by removing one or more glycosylation sites and/or one or more partially glycosylated sites.

17. (previously presented) A method according to claim 15 wherein the underglycosylated ACE protein comprises a mutation at amino acid 337 of SEQ ID No 2 or amino acids 90, 109, 155, 337 and 586 of SEQ ID No 2.

18. (previously presented) A method according claim 15 wherein the ACE protein is crystallised using about 10 mM HEPES and about 0. 1% PMSF with an equal volume of a reservoir solution containing about 15 % PEG 4000, about 50 mM  $\text{CH}_3\text{COONa}\cdot 3\text{H}_2\text{O}$  pH 4.7 and about 10  $\mu\text{M}$   $\text{ZnSO}_4\cdot 7\text{H}_2\text{O}$ .

19. (previously presented) A method according claim 15 wherein the crystal that is prepared has a structure defined by at least a portion of the structure co-ordinates of Table A.

20. (Previously presented) A method according claim 15 wherein the crystal belongs to the space group  $\text{P}2_12_12_1$  or wherein the crystal has the unit cell dimensions:  $a=56.47 \text{ \AA}$ ,  $b=84.90 \text{ \AA}$  and  $c=133.99 \text{ \AA}$ .

21. (canceled)

22. (previously presented) A method according to claim 15 wherein the ACE protein is human ACE protein.

23. (previously presented) A method according to claim 15 wherein the ACE protein is crystallised in the presence of an entity.

24. (previously presented) A method according to claim 23 wherein the entity is a modulator of ACE.

25. (previously presented) A method according to claim 24 wherein the entity is an inhibitor of ACE.

26. (previously presented) A method according to claim 25 wherein the inhibitor of ACE is lisinopril or a derivative thereof.

27. (previously presented) A method according to claim 26 wherein the crystal that is prepared has a structure defined by at least a portion of the structure co-ordinates of Table B.

28-60. (canceled)